Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2015-04-07 Annual Report
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Annual Report 2014
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2014' and contains comprehensive sections typical of a full annual report, including the Chairman's and CEO's statement, business strategy, directors' report, corporate governance report, and full financial statements (income statements, balance sheets, cash flow, and notes). It is a substantial document (over 400,000 characters) and represents the official yearly report of Medivir AB. FY 2014
2015-04-07 English
Kallelse till årsstämma i Medivir AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Medivir AB (publ)" which translates to "Notice of Annual General Meeting in Medivir AB (publ)". The text details the date, time, location, registration procedures, proposed agenda items (including election of board members, approval of financial statements, remuneration guidelines, and incentive programs), and specific proposals to be voted upon at the meeting. This content is characteristic of a formal notice and materials distributed for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2015-04-01 Swedish
Notice of Annual General Meeting of Medivir AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Notice of Annual General Meeting of Medivir AB (publ)" and details the date, time, location, participation requirements, and a detailed proposed agenda for the meeting (items 1 through 18). The agenda covers standard AGM topics like election of the chairman, approval of financial statements, discharge from liability, determination of director fees, and proposals regarding share issuances and incentive programs. This content perfectly matches the definition of materials shared during an Annual General Meeting. Although it mentions the 'annual report' (item 7), the document itself is the notice convening the meeting, not the full 10-K or the standalone Audit Report. It is not a short announcement of a report release (RPA/RNS) because it contains substantial detail about the proposals being voted upon, which is characteristic of AGM materials.
2015-04-01 English
Number of shares and votes in Medivir
Share Issue/Capital Change Classification · 98% confidence The document explicitly states that the number of shares and votes has changed due to a share redemption program resolved in 2014. It provides the new total number of outstanding shares and votes as of the last trading day of March 2015. This content directly relates to a change in the company's capital structure (share count). This aligns best with the 'Share Issue/Capital Change' definition (SHA), which covers changes to the capital structure, including share counts resulting from redemptions or issues. It is not an earnings release (ER), a dividend notice (DIV), or a general regulatory filing (RNS), as it concerns a specific capital structure event.
2015-03-31 English
Antalet aktier och röster i Medivir
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement from Medivir AB regarding a change in the total number of shares and votes following a share redemption program decided in 2014. It explicitly states the new total number of shares (26,966,037) and votes (32,423,259) as of the last trading day of the month (March 2015). This type of announcement, detailing changes in the capital structure (share count/voting rights) due to corporate actions like redemptions, fits best under 'Share Issue/Capital Change' (SHA). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). It is a specific notification about capital structure modification.
2015-03-31 Swedish
New data on Simeprevir presented at the Conference of the Asian Pacific Association for the Study of the Liver
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that new clinical data for their drug simeprevir were presented at a medical conference (APASL 2015). It details the findings from several clinical studies (Phase II and Phase III) regarding cure rates and treatment regimens. The text concludes with standard boilerplate information, contact details, and a statement that Medivir is required under the Securities Markets Act to make the information public, indicating it is a regulatory disclosure. This content is a summary of research findings and business updates, not a formal statutory financial report (like 10-K or IR), a transcript of a call (CT), or a specific proxy/remuneration document. It is an announcement of corporate/scientific progress. Since it is a press release detailing scientific/business progress and is not a specific financial filing type listed (like 10-K, ER, or DIV), it best fits the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a mandatory public disclosure under securities law, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but here it reads like a news release. Given the context of a pharmaceutical company announcing clinical data presentation, this is typically classified as a general regulatory announcement or news release. RNS (Regulatory Filings) is the most appropriate fallback for such non-standard, mandatory disclosures that aren't strictly financial reports or specific corporate actions like dividends or management changes.
2015-03-16 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.